6Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy in locally advanced prostate eancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lan- cet, 2009, 373 (9660) : 301-308.
6Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results, Clin Exp Metastasis, 2003, 20 ( 2 ) : 171-180.
7Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med, 2008, 75 (10): 739 -750.
8Yi B, Williams PJ, Niewolna M, et al. Tumor-derived plateletderived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.Cancer Res, 2002, 62(3): 917-923.
9Drake MT, Clarke BL, Kholsa S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc, 2008, 83 (9) : 1032-1045.
10Wada N, Fujisaki M, Ishii S, et al. Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer, 2001, 8(2) : 131-137.
